Adimab leverages deep experience in multispecifics to support our partners. Solutions include generating large screening panels, enabling Fab and IgG-like formats, and offering anti-CD3 and anti-CD28 antibodies for T cell engager programs. We also work with many partner-suggested formats, including fragment-based bispecifics, as well as offer bespoke engineering services.

Multispecific Screening Panels

Adimab generates large combinatorial panels of multispecific antibodies for partners to screen for their biology of interest.

Solutions for IgG- and Fab-based Multispecific Antibodies

Adimab utilizes common light chain diversities, as well as our proprietary and clinically-tested heterodimerization solutions, to enable a variety of IgG-like and Fab-based multispecific antibodies.

T Cell Engager Platform

Adimab has a toolkit that empowers multispecific antibody T cell engagers

T Cell engager platform

CD3 panel

● Broad affinity range
● Cyno cross-reactive
● Optimized for better developability properties
● Compatible with multiple bispecific formats
● Validated in T cell activation, cytotoxicity, cytokine secretion assays
● Representatives in human clinical trials

1 of 2

CD28 panel

● Broad affinity range
● Multiple bin profiles available with varying agonist potential
● IgG and single domain options
● Compatible with multiple bispecific formats
● Validated in costimulatory T cell activation, cytotoxicity, and cytokine secretion assays

2 of 2

Tools can be extended to molecules with increasing complexity.

Adimab offers a suite of anti-CD3 and anti-CD28 antibodies for incorporation into a partner’s T cell engaging multispecific program. We include multispecific generation and their functional assessment as desired.


We are solely focused on the success of our partners. Therefore, we approach every single project as if it were our own.


Adimab’s best-in-class therapeutic discovery capabilities are made possible by our proprietary yeast-based platform.
Scroll to Top